Aclaris Begins Phase 2b Modzatinib Trial In Lichen Planus, Fast Track-Designated Dual ITK/JAK3 Inhibitor With Potential As First Mechanistically Complete Oral Therapy
Benzinga Newsdesk 2 days ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
- Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral Therapy for Lichen Planus, an Unaddressed Inflammatory Disease with No Approved Therapeutic Options --
- Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral Therapy for Lichen Planus, an Unaddressed Inflammatory Disease with No Approved Therapeutic Options -
- Unique Mechanism Targets Key Pathways Implicated in LP Pathology, T-cell Receptor Signaling Upstream and Effector Cytokine Signaling Downstream -
